CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled / 20 target
Drug / intervention
Give the Placebo and test articledietary
Likely dose
7.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06969469
NCT06969469N/ACompletedUpdate Overdue (0.4/mo)Completion was 27mo ago

To Evaluate the Influence of (LUA Probiotics) on Uric Acid

Grape King Bio Ltd.·observational·Posted May 13, 2025·Updated Jun 22, 2026

In Brief

An observational study evaluating Give the Placebo and test article for Gout. Completed, enrolled 20 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term pharmacological treatments. Hyperuricemia is the presence of abnormally high levels of uric acid in the blood serum. Long-term hyperuricemia is a major factor in causing gout. In addition, hyperuricemia is associated with many diseases. Therefore, the prevention and treatment of hyperuricemia has gradually attracted attention. In recent years, studies have pointed out that whether from cell experiments or animal experiments, lactic acid bacteria (LAB) have the effect of lowering uric acid. However, there is a lack of rigorous clinical observational studies to further explore whether lactic acid bacteria really have the effect of lowering uric acid. This product "LUA Probiotics" is a probiotic developed and produced by the Longtan Branch of Grape King Biotechnology Co., Ltd. Its main ingredients include Lactobacillus reuteri (Lactobacillus reuteri), β-carotene, silicon dioxide and magnesium stearate. This product is not yet commercially available.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 13, 2025
Enrollment StartJul 18, 2022
Primary CompletionMar 29, 2024
Study CompletionAug 8, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 1.1 years ago

Arms & Interventions

Patients with hyperuricemia (uric acid level 7.5 mg/dL or above)other

Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs

Dietary Supplement: Give the Placebo and test article

Interventions

Give the Placebo and test articledietary

Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days. Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.